{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:14:24Z","timestamp":1788786864198,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.semradonc.2025.02.002","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T07:15:23Z","timestamp":1741936523000},"page":"166-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["De-escalation of Adjuvant Therapy in Operatively Managed HPV Associated Oropharyngeal Carcinoma: Current Status and Future Directions"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2957-4687","authenticated-orcid":false,"given":"Daniel","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Routman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.semradonc.2025.02.002_bib0001","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S1470-2045(19)30410-3","article-title":"Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial","volume":"20","author":"Nichols","year":"2019","journal-title":"Lancet Oncol"},{"issue":"34","key":"10.1016\/j.semradonc.2025.02.002_bib0002","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1200\/JCO.24.00119","article-title":"Radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: final results of the ORATOR randomized trial","volume":"42","author":"Nichols","year":"2024","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.semradonc.2025.02.002_bib0003","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMoa032641","article-title":"Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer","volume":"350","author":"Bernier","year":"2004","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.semradonc.2025.02.002_bib0004","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa032646","article-title":"Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck","volume":"350","author":"Cooper","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2025.02.002_bib0005","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.oraloncology.2017.05.009","article-title":"Long-term toxicities in 10-year survivors of radiation treatment for head and neck cancer","volume":"71","author":"Dong","year":"2017","journal-title":"Oral Oncology"},{"issue":"29","key":"10.1016\/j.semradonc.2025.02.002_bib0006","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1200\/JCO.19.01007","article-title":"Phase II trial of de-intensified chemoradiotherapy for Human papillomavirus-associated oropharyngeal squamous cell carcinoma","volume":"37","author":"Chera","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.semradonc.2025.02.002_bib0007","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.20.03128","article-title":"Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002)","volume":"39","author":"Yom","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.02.002_bib0008","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ijrobp.2024.08.014","article-title":"Interim futility results of NRG-HN005, A randomized, phase II\/III non-inferiority trial for non-smoking p16+ oropharyngeal cancer patients","volume":"120","author":"Yom","year":"2024","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"key":"10.1016\/j.semradonc.2025.02.002_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105625","article-title":"Correlation between radiographic and pathologic lymph node involvement and extranodal extension via CT and PET in HPV-associated oropharyngeal cancer","volume":"123","author":"Kowalchuk","year":"2021","journal-title":"Oral Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.02.002_bib0010","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ijrobp.2019.11.021","article-title":"A phase 2 trial of alternative volumes of oropharyngeal irradiation for de-intensification (AVOID): omission of the resected primary tumor bed after transoral robotic surgery for Human papilloma virus-related squamous cell carcinoma of the oropharynx","volume":"106","author":"Swisher-McClure","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2025.02.002_bib0011","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijrobp.2022.06.057","article-title":"A prospective study of mucosal sparing radiation therapy in resected oropharyngeal cancer patients","volume":"115","author":"Anderson","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.semradonc.2025.02.002_bib0012","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1200\/JCO.21.01752","article-title":"Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG-ACRIN cancer research group trial (E3311)","volume":"40","author":"Ferris","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.02.002_bib0013","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.ijrobp.2021.09.012","article-title":"MC1675, a phase III evaluation of de-escalated adjuvant radiation therapy (DART) vs. Standard adjuvant treatment for Human papillomavirus associated oropharyngeal squamous cell carcinoma","volume":"111","author":"Ma","year":"2021","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"issue":"4","key":"10.1016\/j.semradonc.2025.02.002_bib0014","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.ijrobp.2020.09.063","article-title":"Prospective phase 2 study of radiation therapy dose and volume de-escalation for elective neck treatment of oropharyngeal and laryngeal cancer","volume":"109","author":"Sher","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.semradonc.2025.02.002_bib0015","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.ijrobp.2024.08.022","article-title":"A phase II single arm trial of elective volume adjusted de-escalation radiotherapy (EVADER) in patients with low-risk HPV-related oropharyngeal squamous cell carcinoma","volume":"120","author":"Bratman","year":"2024","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"issue":"17","key":"10.1016\/j.semradonc.2025.02.002_bib0016","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1200\/JCO.23.02086","article-title":"Reduced-volume irradiation of uninvolved neck in patients with nasopharyngeal cancer: updated results from an open-label, noninferiority, multicenter, randomized phase III trial","volume":"42","author":"Huang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.semradonc.2025.02.002_bib0017","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1200\/JCO.19.00186","article-title":"Eliminating postoperative radiation to the pathologically node-negative neck: long-term results of a prospective phase II study","volume":"37","author":"Contreras","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2, Supplement","key":"10.1016\/j.semradonc.2025.02.002_bib0018","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.ijrobp.2024.07.050","article-title":"Contralateral neck recurrence rates in head and neck carcinomas after primary surgery, bilateral neck dissection, a pathologically negative Contralateral neck, and adjuvant ipsilateral neck radiation","volume":"120","author":"Kiser","year":"2024","journal-title":"Int J Radiat Oncol*Biol*Phys,"},{"issue":"2","key":"10.1016\/j.semradonc.2025.02.002_bib0019","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/hed.26937","article-title":"An comparison of acute toxicities and patient-reported outcomes between intensity-modulated proton therapy and volumetric-modulated arc therapy after ipsilateral radiation for head and neck cancers","volume":"44","author":"Jeans","year":"2022","journal-title":"Head Neck"},{"key":"10.1016\/j.semradonc.2025.02.002_bib0020","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.radonc.2020.03.010","article-title":"Comparative analysis of acute toxicities and patient reported outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) for the treatment of oropharyngeal cancer","volume":"147","author":"Manzar","year":"2020","journal-title":"Radiother Oncol"},{"issue":"16_suppl","key":"10.1016\/j.semradonc.2025.02.002_bib0021","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.1200\/JCO.2024.42.16_suppl.6006","article-title":"Phase III randomized trial of intensity-modulated proton therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of head and neck oropharyngeal carcinoma (OPC)","volume":"42","author":"Frank","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.02.002_bib0022","doi-asserted-by":"crossref","first-page":"319","DOI":"10.14338\/IJPT-20-00067.1","article-title":"Work outcomes after intensity-modulated proton therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for oropharyngeal cancer","volume":"8","author":"Smith","year":"2021","journal-title":"Int J Part Ther"},{"issue":"16_suppl","key":"10.1016\/j.semradonc.2025.02.002_bib0023","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1200\/JCO.2024.42.16_suppl.6009","article-title":"Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): a trial of the ECOG-ACRIN Cancer Research Group","volume":"42","author":"Burtness","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.02.002_bib0024","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.prro.2024.05.007","article-title":"Radiation therapy for HPV-positive oropharyngeal squamous cell carcinoma: an ASTRO clinical practice guideline","volume":"14","author":"Margalit","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.semradonc.2025.02.002_bib0025","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1186\/s12885-015-1598-x","article-title":"PATHOS: a phase II\/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV) positive oropharyngeal cancer","volume":"15","author":"Owadally","year":"2015","journal-title":"BMC Cancer"},{"issue":"22","key":"10.1016\/j.semradonc.2025.02.002_bib0026","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.19.00463","article-title":"Phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in Human papillomavirus-associated oropharynx squamous cell carcinoma","volume":"37","author":"Ma","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.02.002_bib0027","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.ijrobp.2022.07.377","article-title":"Patient reported outcomes (PROs) in MC1675, de-escalated adjuvant radiation therapy (DART) vs. Standard of care adjuvant radiation therapy (SOC) for HPV associated oropharyngeal squamous cell carcinoma","volume":"114","author":"Routman","year":"2022","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"issue":"5","key":"10.1016\/j.semradonc.2025.02.002_bib0028","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.ijrobp.2021.12.015","article-title":"Non-inferiority margin and nodal analysis of de-escalated adjuvant radiation therapy (DART) for HPV-related oropharyngeal squamous cell carcinoma (OPSCC): a preplanned pooled analysis of MC1273 & MC1675","volume":"112","author":"Ma","year":"2022","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2025.02.002_bib0029","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41591-024-03216-y","article-title":"Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma","volume":"31","author":"Black","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.semradonc.2025.02.002_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.106809","article-title":"Addressing positive multi-cancer early detection tests in head and neck surgery: experience with head and neck work up for high-risk referrals","volume":"152","author":"Fearington","year":"2024","journal-title":"Oral Oncol"},{"issue":"9","key":"10.1016\/j.semradonc.2025.02.002_bib0031","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.annonc.2021.05.806","article-title":"Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set","volume":"32","author":"Klein","year":"2021","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.semradonc.2025.02.002_bib0032","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.19.02444","article-title":"Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer","volume":"38","author":"Chera","year":"2020","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.semradonc.2025.02.002_bib0033","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1158\/1078-0432.CCR-23-1478","article-title":"Negative predictive value of circulating tumor tissue modified viral (TTMV)-HPV DNA for HPV-driven oropharyngeal cancer surveillance","volume":"29","author":"Hanna","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.semradonc.2025.02.002_bib0034","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44783","article-title":"Estimated cost of circulating tumor DNA for posttreatment surveillance of Human papillomavirus-associated oropharyngeal cancer","volume":"5","author":"Kowalchuk","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.semradonc.2025.02.002_bib0035","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/1078-0432.CCR-24-3053","article-title":"A prospective trial of biomarker-guided surveillance for HPV-positive oropharynx cancer using plasma tumor tissue\u2013Modified viral HPV DNA","author":"Rettig","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.02.002_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2022.105721","article-title":"The economic impact of circulating tumor-tissue modified HPV DNA for the post-treatment surveillance of HPV-driven oropharyngeal cancer: a simulation","volume":"126","author":"Ward","year":"2022","journal-title":"Oral Oncol"},{"issue":"11","key":"10.1016\/j.semradonc.2025.02.002_bib0037","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/cncr.34109","article-title":"Cell-free human papillomavirus DNA kinetics after surgery for human papillomavirus-associated oropharyngeal cancer","volume":"128","author":"O'Boyle","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2025.02.002_bib0038","doi-asserted-by":"crossref","DOI":"10.1007\/s00405-025-09218-x","article-title":"Circulating HPVDNA in patients undergoing transoral robotic surgery for oropharyngeal cancer: liquid biopsy could identify molecular residual disease","author":"Campo","year":"2025","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.02.002_bib0039","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/jamaoto.2024.0740","article-title":"Circulating tumor HPV DNA in patients with stage I and II HPV-associated head and neck cancer after surgery","volume":"150","author":"Naegele","year":"2024","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"16_suppl","key":"10.1016\/j.semradonc.2025.02.002_bib0040","doi-asserted-by":"crossref","first-page":"6010","DOI":"10.1200\/JCO.2024.42.16_suppl.6010","article-title":"Prospective validation of ctHPVDNA for detection of minimal residual disease and prediction of recurrence in patients with HPV-associated head and neck cancer treated with surgery","volume":"42","author":"Hirayama","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.02.002_bib0041","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ijrobp.2022.02.012","article-title":"Detectable postoperative circulating tumor Human papillomavirus DNA and association with recurrence in patients with HPV-associated oropharyngeal squamous cell carcinoma","volume":"113","author":"Routman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.semradonc.2025.02.002_bib0042","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.ijrobp.2022.07.378","article-title":"ctHPVDNA and recurrence risk in MC1675, a secondary analysis of a phase III evaluation of de-escalated adjuvant radiation therapy (DART) vs. Standard adjuvant treatment for HPV associated oropharyngeal squamous cell carcinoma","volume":"114","author":"Routman","year":"2022","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"issue":"12","key":"10.1016\/j.semradonc.2025.02.002_bib0043","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S1470-2045(24)00507-2","article-title":"Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2\/3 trial","volume":"25","author":"Mell","year":"2024","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.02.002_bib0044","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.semradonc.2025.02.002_bib0045","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant Nivolumab and Ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med,"},{"key":"10.1016\/j.semradonc.2025.02.002_bib0046","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2024.26886","article-title":"Adjuvant Atezolizumab for early triple-negative breast cancer: the ALEXANDRA\/IMpassion030 randomized clinical trial","author":"Ignatiadis","year":"2025","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.semradonc.2025.02.002_bib0047","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/jamaoncol.2024.1530","article-title":"Neoadjuvant Nivolumab plus chemotherapy followed by response-adaptive therapy for HPV+ oropharyngeal cancer: OPTIMA II phase 2 open-label nonrandomized clinical trial","volume":"10","author":"Rosenberg","year":"2024","journal-title":"JAMA Oncol"},{"issue":"16_suppl","key":"10.1016\/j.semradonc.2025.02.002_bib0048","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.1200\/JCO.2024.42.16_suppl.6017","article-title":"Neoadjuvant HPV16-specific arenavirus-based immunotherapy HB-200 plus chemotherapy followed by response-stratified de-intensification in HPV16+ oropharyngeal cancer: TARGET-HPV","volume":"42","author":"Rosenberg","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.02.002_bib0049","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoto.2024.0480","article-title":"Neoadjuvant chemotherapy and transoral robotic surgery for Human papillomavirus-related oropharyngeal cancer","author":"Sadeghi","year":"2024","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"3","key":"10.1016\/j.semradonc.2025.02.002_bib0050","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ijrobp.2022.02.025","article-title":"The impact of surgical resectability on outcomes for patients undergoing primary radiation treatment for Human papillomavirus-related oropharyngeal cancer","volume":"113","author":"Fnais","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.semradonc.2025.02.002_bib0051","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.annonc.2023.12.007","article-title":"Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST)","volume":"35","author":"Gouda","year":"2024","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.semradonc.2025.02.002_bib0052","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1016\/S1470-2045(24)00066-4","article-title":"Criteria for the diagnosis of extranodal extension detected on radiological imaging in head and neck cancer: head and Neck Cancer International Group consensus recommendations","volume":"25","author":"Henson","year":"2024","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.semradonc.2025.02.002_bib0053","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1200\/JCO.19.02031","article-title":"Multi-institutional validation of deep learning for pretreatment identification of extranodal extension in head and neck squamous cell carcinoma","volume":"38","author":"Kann","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T07:54:10Z","timestamp":1741938850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429625000062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1053429625000062"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.02.002","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"De-escalation of Adjuvant Therapy in Operatively Managed HPV Associated Oropharyngeal Carcinoma: Current Status and Future Directions","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}